FGFR4 and neoplasm: The inefficiency of T cells engineered with CARs containing previously selected scFvs against the full-length protein led the group to improve the biopanning strategy by including selection rounds using only the FGFR4 domain closest to the cell membrane, which likely enhances the performance of CAR-T cells even against tumor cells with low target molecule density.